<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": Review: Reviews Convalescent plasma: possible therapy for novel coronavirus" exact="disease" post="2019 CONVALESENT PLASMA: POSSIBLE THERAPY FOR COVIDâ€�19 Cao and"/>
 <result pre=", This article is being made freely available through PubMed" exact="Central" post="as part of the COVID-19 public health emergency response."/>
 <result pre="the public health emergency.file:TRF-60-1078.pdffig-count: table-count: page-count: word-count: ABBREVIATIONS COVIDâ€�19 coronavirus" exact="disease" post="2019 MERS Middle East respiratory syndrome SARS severe acute"/>
 <result pre="page-count: word-count: ABBREVIATIONS COVIDâ€�19 coronavirus disease 2019 MERS Middle East" exact="respiratory" post="syndrome SARS severe acute respiratory syndrome WHO World Health"/>
 <result pre="word-count: ABBREVIATIONS COVIDâ€�19 coronavirus disease 2019 MERS Middle East respiratory" exact="syndrome" post="SARS severe acute respiratory syndrome WHO World Health Organization"/>
 <result pre="coronavirus disease 2019 MERS Middle East respiratory syndrome SARS severe" exact="acute" post="respiratory syndrome WHO World Health Organization The recent coronavirus"/>
 <result pre="disease 2019 MERS Middle East respiratory syndrome SARS severe acute" exact="respiratory" post="syndrome WHO World Health Organization The recent coronavirus disease"/>
 <result pre="2019 MERS Middle East respiratory syndrome SARS severe acute respiratory" exact="syndrome" post="WHO World Health Organization The recent coronavirus disease 2019"/>
 <result pre="acute respiratory syndrome WHO World Health Organization The recent coronavirus" exact="disease" post="2019 (COVIDâ€�19) epidemic is spreading all over the world."/>
 <result pre="or plasma derivatives obtained from donors who have survived previous" exact="infections" post="by developing antibodies and infusing into newly infected individuals.2"/>
 <result pre="eventually leading to its eradication from the blood circulation. Rapid" exact="viral" post="clearance would prevent further replication and the stimulus for"/>
 <result pre="to be associated with a delay in the peak of" exact="viral" post="replication in a lethal Ebola virusâ€&quot;infected mouse model.3 Another"/>
 <result pre="plasma can convey other healing factors, such as preventing excess" exact="vascular" post="leakage, procoagulant or antifibrinolytic factors, restoring the endothelium glycocalyx.2,"/>
 <result pre="an important role as one of the treatments for many" exact="viral" post="infections when vaccines or other specific treatments are not"/>
 <result pre="important role as one of the treatments for many viral" exact="infections" post="when vaccines or other specific treatments are not available."/>
 <result pre="well documented was the Spanish flu in 1917â€�1919).2 Recently, severe" exact="acute" post="respiratory syndrome (SARS) coronavirus epidemics (2003), A (H5N1) flu"/>
 <result pre="documented was the Spanish flu in 1917â€�1919).2 Recently, severe acute" exact="respiratory" post="syndrome (SARS) coronavirus epidemics (2003), A (H5N1) flu epidemics"/>
 <result pre="was the Spanish flu in 1917â€�1919).2 Recently, severe acute respiratory" exact="syndrome" post="(SARS) coronavirus epidemics (2003), A (H5N1) flu epidemics (2005â€�2015),"/>
 <result pre="plasma therapy. Evidence shows that it is also effective in" exact="infectious diseases" post="such as Lassa fever,13 Argentine hemorrhagic fever,14 measles,15 and"/>
 <result pre="Sin Nombre virus.16 Public Health of England and the International" exact="Severe" post="Acute Respiratory and Emerging Infection Consortium17 put forward that"/>
 <result pre="Nombre virus.16 Public Health of England and the International Severe" exact="Acute" post="Respiratory and Emerging Infection Consortium17 put forward that convalescent"/>
 <result pre="virus.16 Public Health of England and the International Severe Acute" exact="Respiratory" post="and Emerging Infection Consortium17 put forward that convalescent plasma"/>
 <result pre="of England and the International Severe Acute Respiratory and Emerging" exact="Infection" post="Consortium17 put forward that convalescent plasma could be a"/>
 <result pre="could be a promising specific treatment for serious Middle East" exact="respiratory" post="syndrome (MERS), and further evaluation is needed in human"/>
 <result pre="be a promising specific treatment for serious Middle East respiratory" exact="syndrome" post="(MERS), and further evaluation is needed in human clinical"/>
 <result pre="September 2014 that serum from people who are convalescing from" exact="infection" post="with the Ebola virus can be used to treat"/>
 <result pre="of blood volume. Donors needed to be seronegative of HIV," exact="hepatitis" post="B virus, hepatitis C virus, syphilis, and other locally"/>
 <result pre="Donors needed to be seronegative of HIV, hepatitis B virus," exact="hepatitis C" post="virus, syphilis, and other locally transmitted infections.19 CLINICAL TRIAL"/>
 <result pre="CONVALESCENT PLASMA Convalescent plasma has been used to treat several" exact="viral" post="infections, including SARS, avian influenza A (H5N1), influenza A"/>
 <result pre="has been used to treat several viral infections, including SARS," exact="avian influenza" post="A (H5N1), influenza A (H1N1), MERS, and Ebola virus."/>
 <result pre="Many studies have shown that convalescent plasma can effectively reduce" exact="viral" post="load and increase antibodies to inhibit virus replication. Nevertheless,"/>
 <result pre="trials about convalescent plasma showed different results.13 The characteristics of" exact="primary" post="study are described in Table 1. See Table S1"/>
 <result pre="Dose and frequency Titer Outcome SARS Soo6 Clinical Microbiology and" exact="Infection" post="Mean 11.42â€‰days after symptom onset 200â€�400â€‰mL Titer 160â€�2560 Patients"/>
 <result pre="the plasma group had a shorter hospital stay (p=0.001) and" exact="lower" post="mortality (p=0.049) than control group. Wong21 Hong Kong Medical"/>
 <result pre="of Antimicrobial Chemotherapy Unknown 500â€‰mL &amp;gt;640 CP can decrease the" exact="viral" post="load and increase Antiâ€�SARSâ€�CoV IgM and IgG Influenza A/B"/>
 <result pre="Antiâ€�SARSâ€�CoV IgM and IgG Influenza A/B Wu22 International Journal of" exact="Infectious" post="Diseases 10â€‰days after symptom onset 200â€‰mL 80 CP significantly"/>
 <result pre="IgM and IgG Influenza A/B Wu22 International Journal of Infectious" exact="Diseases" post="10â€‰days after symptom onset 200â€‰mL 80 CP significantly decreased"/>
 <result pre="10â€‰days after symptom onset 200â€‰mL 80 CP significantly decreased the" exact="viral" post="load and improved clinical symptoms and signs. Luke24 Annals"/>
 <result pre="â€¦ Early transfusion can significantly reduce the mortality. Hung25 Clinical" exact="Infectious" post="Diseases Day 2 of ICU admission 500â€‰mL &amp;gt;160 CP"/>
 <result pre="Early transfusion can significantly reduce the mortality. Hung25 Clinical Infectious" exact="Diseases" post="Day 2 of ICU admission 500â€‰mL &amp;gt;160 CP reduced"/>
 <result pre="Diseases Day 2 of ICU admission 500â€‰mL &amp;gt;160 CP reduced" exact="respiratory" post="tract viral load, serum cytokine response, and mortality. Xu28"/>
 <result pre="2 of ICU admission 500â€‰mL &amp;gt;160 CP reduced respiratory tract" exact="viral" post="load, serum cytokine response, and mortality. Xu28 â€¦ â€¦"/>
 <result pre="benefit on mortality in patients with severe influenza. Beigel26 Lancet" exact="Respiratory" post="Medicine &amp;lt;24â€‰hours after randomization Two units (225â€�350â€‰mL/unit) &amp;gt;80 CP"/>
 <result pre="randomization Two units (225â€�350â€‰mL/unit) &amp;gt;80 CP was associated with a" exact="lower" post="mortality and improved clinical symptoms, but no statistical significance."/>
 <result pre="and improved clinical symptoms, but no statistical significance. Beigel27 Lancet" exact="Respiratory" post="Medicine &amp;lt;12â€‰hours after randomization (2.2 hours [IQR, 1.7â€�3.3]) 450â€�700â€‰mL"/>
 <result pre="of Medicine 12â€‰days after symptom onset Three 200â€‰mL 80 The" exact="viral" post="load of patients can be quickly removed after transfusion."/>
 <result pre="survival in 84 patients with confirmed EBV. Mupapa29 Journal of" exact="Infectious" post="Diseases 4â€�15â€‰days after symptom onset 150â€�450â€‰mL Unknown Transfusion can"/>
 <result pre="in 84 patients with confirmed EBV. Mupapa29 Journal of Infectious" exact="Diseases" post="4â€�15â€‰days after symptom onset 150â€�450â€‰mL Unknown Transfusion can result"/>
 <result pre="= interquartile range. See Table S1 for detailed data. SARS" exact="infection" post="A retrospective comparative study showed a shorter hospital stay"/>
 <result pre="respond to the ribavirin or methylprednisone. The study shows that" exact="viral" post="load dropped from 495â€‰Ã—â€‰103, 76 Ã—â€‰103, or 65â€‰Ã—â€‰0103 copies/mL"/>
 <result pre="in a timeâ€�dependent manner following convalescent plasma transfusion.22 Influenza A/B" exact="infection" post="Two cases of convalescent plasma were reported. Both showed"/>
 <result pre="of convalescent plasma were reported. Both showed absolute reductions in" exact="viral" post="load. One shows that the H7N9 virus was undetectable,"/>
 <result pre="plasma.9 A lookâ€�back study suggests that patients with Spanish influenza" exact="pneumonia" post="who received transfusion with influenzaâ€�convalescent human blood products may"/>
 <result pre="49/83). Therefore early definitive therapy is of great significance for" exact="pneumonia" post="and hypoxia.24 In 2012, Rockman et al.8 conducted an"/>
 <result pre="[estimated from previous studies as Day 3 after exposure]). A" exact="total" post="of 12 ferrets were included in the treatment group."/>
 <result pre="derived from passive immunization provided immediately before contact with an" exact="infectious" post="dose of virus, compared to buffer controls or H3N2"/>
 <result pre="greater than 160. Mortality in the treatment group was significantly" exact="lower" post="than in the nontreatment group (20.0% vs. 54.8%; p"/>
 <result pre="p = 0.011). Subgroup analysis of 44 patients with serial" exact="respiratory" post="tract viral load and cytokine level demonstrated that plasma"/>
 <result pre="0.011). Subgroup analysis of 44 patients with serial respiratory tract" exact="viral" post="load and cytokine level demonstrated that plasma treatment was"/>
 <result pre="cytokine level demonstrated that plasma treatment was associated with significantly" exact="lower" post="Day 3, 5, and 7 viral load, compared with"/>
 <result pre="was associated with significantly lower Day 3, 5, and 7" exact="viral" post="load, compared with the control group (pâ€‰ 26 One"/>
 <result pre="patients in the plasma plus standard care group normalized their" exact="respiratory" post="status by Day 28 compared with 24 of 45"/>
 <result pre="B virus loads and cytokines after convalescent plasma treatment.28 Ebola" exact="virus infection" post="In 1995, a small study reported that eight patients"/>
 <result pre="virus loads and cytokines after convalescent plasma treatment.28 Ebola virus" exact="infection" post="In 1995, a small study reported that eight patients"/>
 <result pre="levels of neutralizing antibodies in 84 patients with confirmed Ebola" exact="virus infection" post="was not associated with a significant improvement in survival."/>
 <result pre="of neutralizing antibodies in 84 patients with confirmed Ebola virus" exact="infection" post="was not associated with a significant improvement in survival."/>
 <result pre="improvement in survival. Further clinical trial is worth performing. COVIDâ€�19" exact="infection" post="COVIDâ€�19 belongs to the same coronavirus family as SARS"/>
 <result pre="family as SARS and MERS. Many lifeâ€�threatening complications, such as" exact="acute" post="respiratory distress syndrome, can occur during the viral mass"/>
 <result pre="as SARS and MERS. Many lifeâ€�threatening complications, such as acute" exact="respiratory" post="distress syndrome, can occur during the viral mass replication"/>
 <result pre="such as acute respiratory distress syndrome, can occur during the" exact="viral" post="mass replication phase. None of them had specific and"/>
 <result pre="is not available. According to the press conference of the" exact="Joint" post="Prevention and Control Mechanism of the State Council on"/>
 <result pre="mild adverse event was a brief â€œchillâ€� reaction with a" exact="transient" post="hyperpyrexia after the convalescent plasma transfusion. Few patients develop"/>
 <result pre="or anaphylaxis.24 A case report raised an association between transfusionâ€�related" exact="acute" post="lung injury and convalescent plasma.32 OPTIMAL TIMING OF CONVALESCENT"/>
 <result pre="convalescent plasma.32 OPTIMAL TIMING OF CONVALESCENT PLASMA TREATMENT In most" exact="viral" post="illnesses, viremia peaks in the first week of infection."/>
 <result pre="the first week of infection. The patient then develops a" exact="primary" post="immune response by Day 10 to Day 14, followed"/>
 <result pre="rate by Day 22, a shorter hospital stay, and a" exact="lower" post="mortality rate when convalescent plasma was administered before Day14"/>
 <result pre="Day14 of illness onset.5 In a study of patients with" exact="Lassa fever" post="in Nigeria, all eight patients who received convalescent plasma"/>
 <result pre="and clinical symptoms and signs of the patient. There is" exact="limited" post="availability of eligible potential donors with sufficient levels of"/>
 <result pre="plasma is now used as an empirical treatment in the" exact="absence of" post="specific treatment for COVIDâ€�19 and other dangerous viral infections,"/>
 <result pre="the absence of specific treatment for COVIDâ€�19 and other dangerous" exact="viral" post="infections, although its efficacy remains controversial. There are still"/>
 <result pre="Lancet Infect Dis2020;20:398â€�400.32113510 2GarraudO. Use of convalescent plasma in Ebola" exact="virus infection." post="Transfus Apher Sci2017;56:31â€�4.28094110 3GuptaM, MahantyS, BrayM, et al. Passive"/>
 <result pre="of antibodies protects immunocompetent and immunodeficient mice against lethal Ebola" exact="virus infection" post="without complete inhibition of viral replication. J Virol2001;75(10):4649â€�54.11312335 4van"/>
 <result pre="antibodies protects immunocompetent and immunodeficient mice against lethal Ebola virus" exact="infection" post="without complete inhibition of viral replication. J Virol2001;75(10):4649â€�54.11312335 4van"/>
 <result pre="immunocompetent and immunodeficient mice against lethal Ebola virus infection without" exact="complete" post="inhibition of viral replication. J Virol2001;75(10):4649â€�54.11312335 4van GriensvenJ, EdwardsT,"/>
 <result pre="mice against lethal Ebola virus infection without complete inhibition of" exact="viral" post="replication. J Virol2001;75(10):4649â€�54.11312335 4van GriensvenJ, EdwardsT, de LamballerieX, et"/>
 <result pre="LamballerieX, et al. Evaluation of convalescent plasma for Ebola virus" exact="disease" post="in Guinea. N Engl J Med2016;374:33â€�42.26735992 5ChengY, WongR, SooYOY,"/>
 <result pre="care units. Croat Med J2012;53:620â€�6.23275328 11ElbahlawanL, GaurAH, FurmanW, et al." exact="Severe" post="H1N1â€�associated acute respiratory failure in immunocompromised children. Pediatr Blood"/>
 <result pre="Croat Med J2012;53:620â€�6.23275328 11ElbahlawanL, GaurAH, FurmanW, et al. Severe H1N1â€�associated" exact="acute" post="respiratory failure in immunocompromised children. Pediatr Blood Cancer2011;57:625â€�8.21298770 12BrownJF,"/>
 <result pre="Med J2012;53:620â€�6.23275328 11ElbahlawanL, GaurAH, FurmanW, et al. Severe H1N1â€�associated acute" exact="respiratory" post="failure in immunocompromised children. Pediatr Blood Cancer2011;57:625â€�8.21298770 12BrownJF, DyeJM,"/>
 <result pre="al. Severe H1N1â€�associated acute respiratory failure in immunocompromised children. Pediatr" exact="Blood" post="Cancer2011;57:625â€�8.21298770 12BrownJF, DyeJM, TozayS, et al. Antiâ€�Ebola virus antibody"/>
 <result pre="et al. Antiâ€�Ebola virus antibody levels in convalescent plasma and" exact="viral" post="load after plasma infusion in patients with Ebola virus"/>
 <result pre="Infect Dis2018;218:555â€�62.29659889 13FrameJD, VerbruggeGP, GillRG, et al. The use of" exact="Lassa fever" post="convalescent plasma in Nigeria. Trans R Soc Trop Med"/>
 <result pre="Trop Med Hyg1984;78:319â€�24.6464130 14RuggieroHA, PerezIF, MilaniHA, et al. [Treatment of" exact="Argentine hemorrhagic fever" post="with convalescent's plasma. 4433 cases]. Presse Med1986;15:2239â€�42.2949253 15ZingherA, Mortimer.P."/>
 <result pre="Convalescent whole blood, plasma and serum in the prophylaxis of" exact="measles" post="[JAMA, 12 April, 1926; 1180â€�1187]. Rev Med Virol2005;15:407â€�18; discussion"/>
 <result pre="al. Ribavirin, human convalescent plasma and antiâ€�beta3 integrin antibody inhibit" exact="infection" post="by Sin Nombre virus in the deer mouse model."/>
 <result pre="blood or plasma collected from patients recovered from Ebola virus" exact="disease" post="for transfusion, as an empirical treatment during outbreaks. Interim"/>
 <result pre="tool?Blood Transfus2016;14:152â€�7.26674811 21WongVW, DaiD, WuAK, et al. Treatment of severe" exact="acute" post="respiratory syndrome with convalescent plasma. Hong Kong Med J2003;9:199â€�201.12777656"/>
 <result pre="Transfus2016;14:152â€�7.26674811 21WongVW, DaiD, WuAK, et al. Treatment of severe acute" exact="respiratory" post="syndrome with convalescent plasma. Hong Kong Med J2003;9:199â€�201.12777656 22WuX,"/>
 <result pre="21WongVW, DaiD, WuAK, et al. Treatment of severe acute respiratory" exact="syndrome" post="with convalescent plasma. Hong Kong Med J2003;9:199â€�201.12777656 22WuX, GaoH,"/>
 <result pre="WuH, et al. Successful treatment of avianâ€�origin influenza A (H7N9)" exact="infection" post="using convalescent plasma. Int J Infect Dis2015;41:3â€�5.26482389 23YehK, ChiuehT,"/>
 <result pre="SiuLK, et al. Experience of using convalescent plasma for severe" exact="acute" post="respiratory syndrome among healthcare workers in a Taiwan hospital."/>
 <result pre="et al. Experience of using convalescent plasma for severe acute" exact="respiratory" post="syndrome among healthcare workers in a Taiwan hospital. J"/>
 <result pre="al. Experience of using convalescent plasma for severe acute respiratory" exact="syndrome" post="among healthcare workers in a Taiwan hospital. J Antimicrob"/>
 <result pre="Convalescent plasma treatment reduced mortality in patients with severe pandemic" exact="Influenza A (H1N1)" post="2009 virus infection. Clin Infect Dis2011;52:447â€�56.21248066 26BeigelJH, TebasP, Elieâ€�TurenneMC,"/>
 <result pre="mortality in patients with severe pandemic Influenza A (H1N1) 2009" exact="virus infection." post="Clin Infect Dis2011;52:447â€�56.21248066 26BeigelJH, TebasP, Elieâ€�TurenneMC, et al. Immune"/>
 <result pre="convalescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: a systematic review and"/>
 <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: a systematic review and exploratory"/>
 <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: a systematic review and exploratory metaâ€�analysis."/>
 <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: a systematic review and exploratory metaâ€�analysis. J Infect"/>
 <result pre="exploratory metaâ€�analysis. J Infect Dis2014;211:80â€�90.25030060 32Moraâ€�RilloM, ArsuagaM, Ramirezâ€�OlivenciaG, et al." exact="Acute respiratory distress syndrome" post="after convalescent plasma use: treatment of a patient with"/>
 <result pre="metaâ€�analysis. J Infect Dis2014;211:80â€�90.25030060 32Moraâ€�RilloM, ArsuagaM, Ramirezâ€�OlivenciaG, et al. Acute" exact="respiratory" post="distress syndrome after convalescent plasma use: treatment of a"/>
 <result pre="Infect Dis2014;211:80â€�90.25030060 32Moraâ€�RilloM, ArsuagaM, Ramirezâ€�OlivenciaG, et al. Acute respiratory distress" exact="syndrome" post="after convalescent plasma use: treatment of a patient with"/>
 <result pre="convalescent plasma use: treatment of a patient with Ebola virus" exact="disease" post="contracted in Madrid, Spain. Lancet Respir Med2015;3:554â€�62.26041403 33LongQâ€�x, DengHâ€�j,"/>
 <result pre="Madrid, Spain. Lancet Respir Med2015;3:554â€�62.26041403 33LongQâ€�x, DengHâ€�j, ChenJ, et al." exact="Antibody" post="responses to SARSâ€�CoVâ€�2 in COVIDâ€�19 patients: the perspective application"/>
</results>
